• 1
    Colombo M, De Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 67580.
  • 2
    Mathurin P, Rixe O, Carbonel N, et al. Overview of medical treatments in hepatocellular carcinoma: an impossible meta-analysis? Aliment Pharmacol Ther 1998; 12: 11126.
  • 3
    Simonetti RG, Liberati A, Anglioni C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997; 8: 11736.
  • 4
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2002; 37: 42942.
  • 5
    Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995; 197: 1018.
  • 6
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinoma with cirrhosis. N Engl J Med 1996; 334: 6939.
  • 7
    Bruix J, Cirera I. Surgical resection and survival in western patients with hepatocellular carcinoma. J Hepatol 1992; 15: 3505.
  • 8
    Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993; 218: 14551.
  • 9
    Ringe B, Pichlmayr R, Wittekind C, Tussch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991; 15: 27085.
  • 10
    Bruix J, Sherman M, Llovet JM, et al. for the EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35: 42130.
  • 11
    Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992; 16: 3537.
  • 12
    Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 12249.
  • 13
    Liovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 143440.
  • 14
    Shimada M, Takenaka K, Gion T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 1996; 111: 7206.
  • 15
    Ishii H, Okada S, Nose H, et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 1996; 77: 17926.
  • 16
    Castellano L, Calandra M, Del Vecchio Blanco C, De Sio I. Predictive factors of survival and intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after percutaneous ethanol injection: analysis of 71 patients. J Hepatol 1997; 27: 86270.
  • 17
    Castells A, Bruix J, Bru C, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993; 18: 11216.
  • 18
    The Liver Cancer Study Group of Japan. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular cancer in Japan. Cancer 1994; 74: 277280.
  • 19
    Sacks HS, Berrier J, Reitman D, Angoma-Berk VA, Chalmers TC. Meta-analysis of randomized controlled trials. N Engl J Med 1987; 19: 4505.
  • 20
    Ozminkowski RJ, Wortman PM, Roloff DW. Inborn/outborn status and neonatal survival: a meta-analysis of non-randomized studies. Stat Med 1988; 7: 120721.
  • 21
    Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34: 593602.
  • 22
    Poynard T, Conn HO. The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of medlars and manual methods. Control Clin Trials 1985; 6: 2719.
  • 23
    El-Serag H, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001; 33: 625.
  • 24
    Liovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000; 31: 101921.
  • 25
    Bruix J, Liovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 51924.
  • 26
    Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997; 25: 25961.
  • 27
    Ono T, Yamanoi A, El Assal OM, Kohno H, Nagasue N. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients. Cancer 2001; 91: 237885.
  • 28
    Partensky C, Sassolas G, Henry L, Paliard P, Maddern GJ. Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma. Arch Surg 2000; 135: 1298300.
  • 29
    Roseman BJ, Roh MS. Prognosis factors in surgical resection for hepatocellular carcinoma. Cancer Treat Res 1997; 90: 33145.
  • 30
    Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000; 232: 1024.
  • 31
    Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised controlled trial. Lancet 1999; 353: 797801.
  • 32
    Lau H, Fan ST, Ng IO, Wong J. Long term prognosis after hepatectomy for hepatocellular carcinoma: a survival analysis of 204 consecutive patients. Cancer 1998; 83: 230211.
  • 33
    Bronowicki JP, Boudjema K, Chone L, Nisand G, Bazin C, Doffoel M. Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma. J Hepatol 1996; 24: 293300.
  • 34
    Okada S, Shimada K, Yamamoto J, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 1994; 106: 161824.
  • 35
    Poynard T. Evaluation de la qualité méthodologique des essais thérapeutiques randomisés. Presse Med 1988; 17: 3158.
  • 36
    Demets DL. Methods of combining randomized clinical trials: strength and limitations. Stat Med 1987; 6: 3418.
  • 37
    Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 17788.
  • 38
    The San-In Group of Liver Surgery. Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: a prospective randomized trial. Br J Surg 1997; 84: 152531.
  • 39
    Fan ST, Lo CM, Lai EC, Chu KM, Liu CL, Wong J. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994; 331: 154752.
  • 40
    Ziegler TR. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. J Parenter Enteral Nutr 1996; 20: 912.
  • 41
    Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 8027.
  • 42
    Kawata A, Une Y, Hosokawa M, et al. Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphocyte-activated killer cells versus adriamycin alone. Am J Clin Oncol 1995; 18: 25762.
  • 43
    Uchino J, Une Y, Kawata A, Wakisaka Y , Hosokawa M. Postoperative chemoimmunotherapy for the treatment of liver cancer. Semin Surg Oncol 1993; 9: 3326.
  • 44
    Yoshida T, Sakon M, Umeshita K, et al. Appraisal of transarterial immunoembolization for hepatocellular carcinoma: a clinicopathologic study. J Clin Gastroenterol 2001; 32: 5965.
  • 45
    Muto Y, Moriwaki H, Ninomya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996; 334: 15617.
  • 46
    Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32: 22832.
  • 47
    Huang YH, Wu JC, Lui WY, et al. Prospective case-controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma. World J Surg 2000; 24: 5515.
  • 48
    Hwang TL, Chen MF, Lee TY, Chen TJ, Lin DY, Liaw YF. Resection of hepatocellular carcinoma after transcatheter arterial embolization. Arrch Surg 1987; 122: 7569.
  • 49
    Takayasu K, Shima Y, Muramatsu Y, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutics agents. Radiology 1987; 162: 34551.
  • 50
    Stefanini GF, Foschi FG, Marsigli L, et al. Alpha-1 thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience. Hepatogastroenterology 1998; 45: 20915.
  • 51
    Lygidakis NJ, Pothoulakis J, Konstantinidou A, Spanos H. Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy–chemotherapy. A prospective randomized study. Anticancer Res 1995; 15: 54350.
  • 52
    Izumi R, Shimizu K, Miyazaki I. Postoperative adjuvant locoregional chemotherapy in patients with hepatocellular carcinoma. Hepatogastroenterology 1996; 43: 141520.
  • 53
    Ikeda K, Saitoh S, Koida I, et al. A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 1995; 18: 20410.
  • 54
    Lygidakis NJ, Tsiliakos S, Tallat A, Matsakis G , Tepetes K. Multidisciplinary management of hepatocellular carcinoma. Hepatogastroenterology 1997; 44: 26873.
  • 55
    Tang ZY, Zhou HY, Zhao G, et al. Preliminary result of mixed bacterial vaccine as adjuvant treatment of hepatocellular carcinoma. Med Oncol Tumor Pharmacother 1991; 8: 238.
  • 56
    Osaka Study Group on Hepatocellular Carcinoma. Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization treated patients with resectable or non-resectable hepatocellular carcinoma. Cancer Chemother Pharmacol 1989; 23(Suppl.): 29S32S.
  • 57
    Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg 2000; 231: 54451.
  • 58
    Nakashima K, Kitano S, Kim YI, Aramaki M, Kawano K. Postoperative adjuvant arterial infusion chemotherapy for patients with hepatocellular carcinoma. Hepatogastroenterology 1996; 43: 14104.
  • 59
    Zhang Z, Liu Q, He J, Yang J, Yang G, Wu M. The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer 2000; 89: 260612.
  • 60
    Naomi T, Isshiki K, Katoh H, et al. The potential role of postoperative hepatic artery chemotherapy in patients with high-risk hepatomas. Ann Surg 1991; 213: 2226.
  • 61
    Harada A, Nonami T, Kishimoto W, Nakao T , Tagaki H. Results of hepatic resection and postoperative arterial chemotherapy for hepatocellular carcinoma. Cancer Chemother Pharmacol 1992; 31: S357.
  • 62
    Monden M, Okamura J, Sakon M, et al. Significance of transcatheter chemoembolization combined with surgical resection for hepatocellular carcinomas. Cancer Chemother Pharmacol 1989; 23: S905.
  • 63
    Wu CC, Oho YZ, Lin Ho W, Wu TC, Liu TJ, Peng FK. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995; 82: 1226.
  • 64
    Yamasaki S, Hasegawa H, Kinoshita H, et al. A prospective randomized trial of preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellualar carcinoma. Jpn J Cancer Res 1996; 87: 20611.
  • 65
    Adachi E, Matsumata T, Nishizaki T, Hashimoto H, Tsuneyoshi M. Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. Cancer 1993; 72: 35938.
  • 66
    Majno PE, Adam R, Bismuth H, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226: 688703.
  • 67
    Harada T, Matsuo K, Inoue T, Tamesue S, Inoue T, Nakamura H . Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma. Ann Surg 1996; 224: 49.
  • 68
    Nagasue N, Galizia G, Kohno H, et al. Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma. A retrospective comparison of 138 liver resections. Surgery 1989; 106: 816.
  • 69
    Paye F, Jagot P, Vilgrain V, Farges O, Borie D, Belghiti J. Preoperative chemoembolization of hepatocellular carcinoma. Arch Surg 1998; 133: 76772.
  • 70
    Uchida M, Khono H, Kubota H, et al. Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg 1996; 20: 32631.
  • 71
    Imaoka S, Sasaki Y, Shibata T, et al. A pre-operative chemoembolization therapy using lipiodol, cisplatin and gelatin sponge for hepatocellular carcinoma. Cancer Chemother Pharmacol 1989; 23: S1268.
  • 72
    Izumi R, Shimizu S, Iyobe T, et al. Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 1994; 20: 295301.
  • 73
    Li JQ, Zhang YK, Zhang WZ, Yuan YF, Li GH. Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy. J Cancer Res Clin Oncol 1995; 121: 3646.
  • 74
    Ueno S, Tanabe G, Yoshida A, Yoshidome S, Takao S, Aikou T. Postoperative prediction of and strategy for metastatic recurrent hepatocellular carcinoma according to histologic activity of hepatitis. Cancer 1999; 86: 24854.
  • 75
    Takenaka K, Yoshida K, Nishizaki T, et al. Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocelllular carcinoma. Am J Surg 1995; 169: 4005.
  • 76
    Tanaka K, Shimada H, Togo S, et al. Use of transcatheter arterial infusion of anti-cancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection. Hepatogastroenterology 1999; 46: 10838.
  • 77
    Asahara T , Itamoto T, Katayama K, et al. Adjuvant hepatic arterial infusion chemotherapy after radical hepatectomy for hepatocellular carcinoma — results of long-term follow-up. Hepatogastroenterology 1999; 46: 10428.
  • 78
    Yamamoto M, Arii S, Sughara K, Tobe T. Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg 1996; 83: 33640.
  • 79
    Lai EC, Lo CM, Fan ST, Liu CL, Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 1998; 133: 1838.
  • 80
    Ono T, Nagasue N, Kohno H, et al. Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin Oncol 1997; 24(2 Suppl. 6): S618, S6–25.
  • 81
    Khono H, Nagasue N, Hayashi T, et al. Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Hepatogastroenterology 1996; 43: 14059.
  • 82
    Poynard T, Munteanu M, Ratziu V, et al. Truth survival in clinical research: an evidence-based requiem? Ann Intern Med 2002; 136: 88895.